Skip to main content
Premium Trial:

Request an Annual Quote

Michael Vicari

OncoCyte has appointed Michael Vicari to a newly created position of vice president of sales, in which he will report directly to president and CEO William Annett. In his new role, Vicari will be responsible for the development and successful implementation of domestic and international sales strategies for OncoCyte, with an initial focus on the expected fourth quarter US launch of the firm's liquid biopsy lung cancer test DetermaVu.

Vicari comes with 35 years of successful sales and marketing leadership within the healthcare industry, including the launch of several important diagnostic products, OncoCyte said. He previously worked with Eurofins Scientific as VP of sales & marketing for the company's clinical diagnostics business. Prior to Eurofins, he was VP of sales for Sequenom, for Monogram Biosciences, and served in senior commercial leadership roles at Genentech, Corixa Oncology, and MedImmune.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.